This is investment research, not personal financial advice.
The 4.7% fall is small only beside the size of the debate
ResMed (ASX:RMD) was down 4.7% in the late-morning ASX scan at A$28.63, a move that erased roughly A$2 billion of equity value on the CDI line when measured against the quoted ASX price and an author-estimated 1.47 billion CDI-equivalent share count (Yahoo Finance 2026; ASX 2026). There was no single fresh ASX price-sensitive operating announcement before lunch. That matters. The market event was a sentiment repricing in a large, liquid healthcare name whose central controversy has been visible for more than a year: whether obesity drugs reduce the future pool of obstructive sleep-apnoea patients who need continuous positive airway pressure devices.
The commissioning question is therefore narrower than a full-company initiation note. Did Monday's selloff correctly mark down ResMed's device economics, or did it capitalise a GLP-1 fear that the financial record has not yet confirmed? The evidence points to a proportionate but still unproven reaction. The price now sits around the lower half of a base-case range built from FY2025 free cash flow, but the severe downside only works if obesity-drug adoption starts showing up in new-device growth, mask replenishment and cash conversion. Those disclosures, not the one-day share-price move, will decide the argument.
The trigger is unusual because it is not an ASX filing. It is the tape reacting to a theme. That lowers verification confidence for the market-cause layer, and the article treats the cause accordingly. The company layer is firmer: ResMed's filings show a high-margin medical-device and software business, reporting in US dollars, with improving cash generation and lower net debt through FY2025 (ResMed 2025). The event layer asks how much of that evidence a 4.7% fall should displace.
What ResMed actually sells, and why the model is not a one-device bet
ResMed sells devices, masks, accessories and software for sleep and respiratory care. The listed ASX line is a CDI exposure to ResMed Inc., which reports in US dollars, so the AUD financial table in this article uses an A$1.52 per US$ translation. The translation is an author bridge for comparability with the ASX price; the underlying accounts are USD accounts (ResMed 2025).
The business has two economic layers. The first is the device start: diagnosis, prescription, set-up and patient adherence. The second is the replenishment and support stream: masks, accessories, connected-care data and software. The GLP-1 concern attacks the first layer. If obesity drugs reduce obstructive sleep-apnoea prevalence or severity, fewer new patients may need therapy. But the second layer means the equity value is not a pure new-device-start multiple. A large installed base can keep buying consumables and software even if the flow of new starts slows.
That split is why the Monday fall cannot be judged by the obesity headline alone. A direct substitute would show up first in devices revenue, then in mask replenishment, then in free cash flow. A diagnosis-expansion effect would look different: more treated obesity patients being screened for sleep apnoea, with a portion still needing device therapy. ResMed's own FY2025 numbers do not settle that clinical question, but they make the bar clear. Device weakness must be large enough to overwhelm recurring revenue, gross margin and operating leverage before a permanent valuation reset is justified.
The peer context also matters. Philips remains the obvious respiratory-care reference point, but its sleep franchise has carried its own recall and remediation history, so peer comparison is imperfect (Philips 2025). ResMed has benefited from execution while a major competitor was distracted. The market now has to separate two things that can look alike in a price chart: loss of temporary share gains as a competitor normalises, and structural loss of demand because the patient pool changes.
The financial record has improved, not deteriorated
The history table below is author-translated to AUD at A$1.52 per US$ and rounds the reported USD accounts. ROIC is author-computed using after-tax operating profit against average invested capital where available, with simplifications because the public article is not reproducing every balance-sheet line. The metric is directionally useful, not a company-reported figure.
| Year | Revenue (A$m) | NPAT (A$m) | FCF (A$m) | computed ROIC | Net debt (A$m) |
|---|---|---|---|---|---|
| FY2022 | 5,439 | 1,184 | 535 | 15% | 1,080 |
| FY2023 | 6,388 | 1,360 | 430 | 14% | 2,200 |
| FY2024 | 7,053 | 1,531 | 1,900 | 17% | 1,240 |
| FY2025 | 7,835 | 1,925 | 2,130 | 20% | 760 |
The table argues against a business already rolling over. Revenue grew from roughly A$5.4 billion in FY2022 to A$7.8 billion in FY2025, and free cash flow recovered sharply after the FY2023 working-capital trough (ResMed 2022; ResMed 2023; ResMed 2024; ResMed 2025). Net debt fell as cash conversion improved. Those are the numbers a market normally capitalises at a premium: high gross margins, a defensible channel, recurring consumables, and free cash flow that can fund reinvestment and buybacks without stretching the balance sheet.
The incremental return picture is also cleaner in FY2024-FY2025 than it was in FY2023. On the author-computed bridge, FY2025 added about A$782 million of revenue and about A$230 million of free cash flow versus FY2024. Against a lower net-debt base and a stable capital structure, that is not the pattern of a device maker losing relevance. It is the pattern of a business still converting scale into cash.
There are caveats. The translation rate can move the AUD table even when the USD business does not. ROIC is sensitive to goodwill, acquired intangibles and working-capital timing. Free cash flow can run ahead of earnings when inventory unwinds. None of that changes the main point: the burden of proof for a permanent derating sits with future demand data, not with the backward financial record.
The owner-earnings bridge is the crux of the valuation
For valuation, ResMed is best treated as a global medical-device and connected-care compounder rather than a commodity healthcare manufacturer. The relevant bridge starts with owner earnings. FY2025 free cash flow was about A$2.1 billion after translation. Maintenance capital expenditure is not separately disclosed in the compact table, so the article uses reported free cash flow as the cleanest owner-earnings proxy and treats growth reinvestment as embedded in the operating model.
At A$28.63 per ASX CDI and an estimated market value of A$42.1 billion, the stock traded near 19.8 times FY2025 free cash flow. That multiple is not low in an absolute sense. It requires confidence that cash flow can grow and that device demand will not be structurally impaired. The selloff reduced that confidence price, but it did not push the stock into a deep-distress valuation.
The reverse question is more useful than a single-point value. A mature medtech business growing free cash flow at low single digits and carrying more device-cycle risk might deserve 14-16 times owner earnings, which maps to the severe downside and bear ranges. A business with mid-single-digit revenue growth, stable masks/accessories replenishment and modest margin expansion can support something closer to 18-22 times. A business where GLP-1 treatment expands diagnosis and ResMed keeps taking share can still justify a higher multiple.
That framework produces four observational scenarios. Severe downside is A$18-22 per CDI: GLP-1 adoption cuts new patient growth, device margins compress, and the market treats ResMed as a no-growth hardware business. Bear is A$23-28: devices slow, recurring revenue offsets part of the pressure, and the multiple resets toward mature medtech. Base is A$29-35: FY2025 free cash flow grows at a modest rate and the company retains a premium for cash quality. Bull is A$38-46: diagnosis expands, the obesity-drug threat proves overstated, and margins keep widening.
The post-move price sits just below the base range midpoint and near the top of the bear range. That is a fair place for uncertainty to show up. It is not yet a price that assumes the sleep-apnoea franchise is broken.
The market is capitalising a risk before the operating line item has confirmed it
The causal chain behind the selloff is plausible. Obesity is a major risk factor for sleep apnoea, and GLP-1 drugs target obesity. If those drugs materially reduce the number of patients needing device therapy, ResMed's terminal growth should be lower. The World Health Organization's obesity data keeps the addressable-patient backdrop large, but a large population does not guarantee device starts if treatment pathways shift (WHO 2026).
The missing link is evidence of substitution at scale. A medicine that reduces weight can still leave many patients needing airway support. It may also bring more patients into medical assessment, raising diagnosis rates. ResMed's FY2026 quarterly releases are the right place to test which effect is winning. Device revenue below 3% growth for two consecutive quarters would turn sentiment into operating evidence. Masks and accessories slowing at the same time would be more serious because it would suggest the installed-base offset is weakening.
Regulatory context is less dramatic than the share-price move. Positive airway pressure devices remain regulated medical devices used for diagnosed patients; the FDA device framework has not disappeared because obesity pharmacology improved (FDA 2026). The question is clinical practice and payer behaviour, not whether the device category has lost regulatory legitimacy.
Capital allocation adds another test. The balance sheet improved into FY2025, with net debt lower on the author-translated table. That gives management room, but room can be spent badly. A large acquisition or buyback programme that raises leverage before the GLP-1 question is settled would make the equity story more dependent on financial engineering. Conservative leverage would keep the debate focused on demand and cash conversion.
Reaction verdict: proportionate caution, not confirmed impairment
The 4.7% fall looks proportionate as a risk-marking exercise. ResMed entered the session priced for high-quality medtech cash flows, and high-quality multiples are sensitive when investors reprice terminal growth. A one-day fall of that size is consistent with the market moving the stock from a clean compounder lens toward a contested-growth lens.
But the evidence does not yet support a conclusion that the device franchise has been structurally impaired. FY2022-FY2025 financials show revenue growth, stronger free cash flow and improving returns. The owner-earnings multiple after the fall still assumes resilience, but not perfection. The bear case needs future device and mask data to deteriorate. The severe downside needs a clearer substitution signal than a sentiment-led ASX move.
This is the monitoring plan for the next disclosures. First, devices revenue: below 3% growth for two consecutive quarters would show the patient-start funnel is slowing. Second, masks and accessories: if recurring revenue weakens at the same time, the installed-base defence loses force. Third, free cash flow conversion: if cash conversion drops below 75% of adjusted net income, the valuation debate moves from GLP-1 narrative to earnings quality. Fourth, leverage: net debt above 1.5 times EBITDA after discretionary capital allocation would change the risk profile.
The market is now pricing ResMed as a company whose moat is still intact but whose terminal-growth assumption deserves a haircut. The next answer will not come from another intraday price move. It will come from FY2026 device growth, replenishment revenue and cash conversion, where the GLP-1 theory either starts to bite the accounts or remains a valuation fear sitting ahead of the evidence.
Source notes
Verification is partial. The ASX issuer page, Yahoo Finance chart endpoint and company investor-relations pages were fetched during the run, but MarketIndex returned a 403 and the AFR market page is listed only as unfetched context with no figures attributed to it. The financial table uses ResMed's USD reporting base translated at A$1.52 per US$; ROIC and scenario values are author calculations, not source-reported metrics. The missing information is the precise intraday ASX volume comparison and a company filing that directly attributes Monday's fall to GLP-1 sentiment. The article therefore treats the price move as verified and the causal mechanism as an evidence-based market interpretation.
References
- ASX 2026: ASX company page for ResMed Inc. (RMD), used for legal identity and ASX market-page context.
- Yahoo Finance 2026: Yahoo Finance chart snapshot for ASX:RMD, used for the late-morning share-price move.
- ResMed 2022: ResMed Inc. FY2022 Form 10-K and annual financial data, used for the historical table.
- ResMed 2023: ResMed Inc. FY2023 Form 10-K and annual financial data, used for the historical table.
- ResMed 2024: ResMed Inc. FY2024 Form 10-K and annual financial data, used for the historical table.
- ResMed 2025: ResMed Inc. FY2025 Form 10-K and annual financial data, used for the historical table and owner-earnings bridge.
- ResMed 2026a: fiscal 2026 third-quarter release context for near-term device and cash-flow monitoring.
- FDA 2026: FDA medical-device information for regulatory context.
- WHO 2026: obesity macro context for the GLP-1/sleep-apnoea debate.
- Philips 2025: peer respiratory-care context.
- AFR 2026: market-context source listed as not fetched; no figures are attributed to it.